tiprankstipranks
Trending News
More News >
Sotera Health (SHC)
NASDAQ:SHC

Sotera Health (SHC) AI Stock Analysis

Compare
182 Followers

Top Page

SH

Sotera Health

(NASDAQ:SHC)

Rating:61Neutral
Price Target:
$12.00
▲(3.09%Upside)
Sotera Health's overall stock score is primarily influenced by its solid financial performance and positive earnings outlook, despite high leverage and valuation concerns. The technical analysis indicates bearish trends, and the legal settlement poses potential risks, but the company's growth prospects and strategic initiatives offer resilience.
Positive Factors
Regulatory Impact
Nelson volumes are benefiting from new regulatory requirements across various end-markets, including bioprocessing and medtech.
Volume Trends
Management is confident in volume recovery, with volumes stabilizing after pandemic-related volatility and positive trends in bioprocessing, medtech, and general hospital sectors.
Negative Factors
Financial Performance
Unfavorable revisions to EBITDA and increased interest expenses have negated the potential benefits from increased discipline around growth capex.
Revenue Decline
The company faces a significant decline in RCA-related revenue in the first quarter, leading to a solidly negative volume and mix.

Sotera Health (SHC) vs. SPDR S&P 500 ETF (SPY)

Sotera Health Business Overview & Revenue Model

Company DescriptionSotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
How the Company Makes MoneySotera Health generates revenue primarily through its diverse portfolio of sterilization and lab testing services offered across its three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics is a major source of income, providing various sterilization methods, including gamma, ethylene oxide, and electron beam, to healthcare manufacturers. Nordion contributes by supplying Cobalt-60, essential for gamma sterilization and radiation therapy. Nelson Labs supports revenue through its comprehensive suite of microbiology testing and laboratory services, catering to healthcare, pharmaceutical, and medical device companies. The company's earnings are bolstered by long-term contracts with clients, strategic partnerships, and its global presence, all contributing to a stable and diversified revenue stream.

Sotera Health Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q1-2025)
|
% Change Since: 1.22%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
Sotera Health demonstrated robust growth in revenues and EBITDA, notably in Nelson Labs and Nordion, and maintained a positive outlook for 2025. However, challenges such as the Cobalt-60 shipment timing, a GAAP net loss due to legal settlements, and revenue decline in Nelson Labs advisory services were noted. Despite these lowlights, the positive developments and reaffirmed growth outlook suggest a resilient performance.
Q1-2025 Updates
Positive Updates
Solid Start to 2025 with Revenue and EBITDA Growth
Sotera Health reported a 2.6% increase in total company revenues, or 4.4% on a constant currency basis, for Q1 2025 compared to Q1 2024. Adjusted EBITDA increased by 8.8%, or 11.2% on a constant currency basis.
Nelson Labs Margin Expansion
Nelson Labs achieved a 479 basis point margin expansion versus Q1 2024, marking the third consecutive quarter of year-over-year margin expansion.
Nordion's Strong Revenue Performance
Nordion's revenue increased by 36% to $33 million, or 40.6% on a constant currency basis, compared to Q1 2024. Segment income increased approximately 62%.
Reaffirmed 2025 Outlook
Sotera Health reaffirmed its 2025 outlook, expecting revenue growth in the range of 4% to 6% and adjusted EBITDA growth of 4.5% to 6.5% on a constant currency basis.
Successful Amendment to Revolving Credit Facility
The amendment added approximately $175 million in liquidity, extending maturity to April 2030.
FDA Clearance for Bionic Pancreas
Sotera Health played a critical role in securing FDA clearance for the first-ever bionic pancreas, showcasing the integrated expertise of Nelson Labs and Sterigenics.
Negative Updates
Impact of Cobalt-60 Shipment Timing on Nordion
Nordion's Q1 revenue exceeded expectations due to a shift in Cobalt-60 shipments, which will impact Q2 revenue.
Net Loss Due to Settlement of EO Claims
Sotera Health reported a GAAP net loss of $13 million, or $0.05 per diluted share, due to a $31 million settlement of EO claims in Illinois.
Decline in Nelson Labs Advisory Services Revenue
Nelson Labs experienced a decline in revenue by 9.3% due to a decrease in expert advisory services, despite offsetting improvements in core lab testing.
Foreign Currency Headwinds
Foreign currency presented a 180 basis point headwind for the quarter, most pronounced in the Canadian-based Nordion business.
Company Guidance
During the first quarter of 2025 earnings call, Sotera Health provided guidance indicating a strong start to the year, with revenue increasing by 2.6% or 4.4% on a constant currency basis compared to Q1 2024. The company reported an adjusted EBITDA growth of 8.8% or 11.2% on a constant currency basis. The adjusted EPS for the quarter was $0.14, showing a $0.01 improvement from the previous year. Sotera reaffirmed their full-year 2025 outlook, expecting revenue growth between 4% to 6% and adjusted EBITDA growth of 4.5% to 6.5% on a constant currency basis. The company anticipates a foreign exchange headwind of approximately 1.25% on revenue and 1.5% on adjusted EBITDA. Additionally, Sotera expects a net leverage ratio improvement, with capital expenditures projected between $190 million to $210 million for 2025, and a goal to generate $500 million to $600 million in free cash flow over the next three years.

Sotera Health Financial Statement Overview

Summary
Sotera Health shows consistent revenue growth and strong operational efficiency with solid EBITDA margins. However, high leverage and fluctuating net profits pose potential risks, despite effective cash flow management.
Income Statement
72
Positive
Sotera Health shows a consistent revenue growth trend with a 7.1% increase from 2023 to TTM and a 4.5% increase from 2022 to 2023. The gross profit margin is stable, averaging around 54% over the periods. However, net profit margin has fluctuated, showing a decline in TTM due to lower net income. EBITDA margin remains robust, indicating strong operational efficiency.
Balance Sheet
65
Positive
The company's balance sheet reveals a high debt-to-equity ratio of 5.67 in TTM, which poses a leverage risk. The equity ratio is relatively low at 13.4%, suggesting limited financial flexibility. Return on equity has decreased, reflecting weaker profitability relative to equity.
Cash Flow
68
Positive
Free cash flow has shown positive growth from 2023 to TTM, indicating efficient capital management. The operating cash flow to net income ratio is favorable, signifying good cash generation relative to earnings. However, fluctuations in capital expenditures impact overall cash flow stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.11B1.10B1.05B1.00B931.48M818.16M
Gross Profit610.61M602.29M577.16M557.00M518.67M443.57M
EBITDA415.84M442.20M406.83M-17.41M400.81M319.96M
Net Income24.82M44.40M51.38M-233.57M116.88M-38.62M
Balance Sheet
Total Assets3.10B3.07B3.13B3.12B2.79B2.76B
Cash, Cash Equivalents and Short-Term Investments304.39M277.24M296.41M395.21M106.92M102.45M
Total Debt2.35B2.35B2.33B2.03B1.83B1.91B
Total Liabilities2.68B2.67B2.69B2.77B2.20B2.31B
Stockholders Equity414.09M404.91M443.73M350.24M586.10M452.30M
Cash Flow
Free Cash Flow75.13M45.09M-362.71M95.58M179.38M67.08M
Operating Cash Flow239.22M224.16M-147.73M277.96M281.55M120.58M
Investing Cash Flow-164.02M-179.00M-214.91M-181.90M-159.83M-158.69M
Financing Cash Flow-15.95M-50.56M265.96M197.76M-117.29M73.43M

Sotera Health Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price11.64
Price Trends
50DMA
12.01
Negative
100DMA
11.98
Negative
200DMA
13.25
Negative
Market Momentum
MACD
-0.21
Negative
RSI
49.87
Neutral
STOCH
64.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHC, the sentiment is Neutral. The current price of 11.64 is above the 20-day moving average (MA) of 11.59, below the 50-day MA of 12.01, and below the 200-day MA of 13.25, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 49.87 is Neutral, neither overbought nor oversold. The STOCH value of 64.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SHC.

Sotera Health Risk Analysis

Sotera Health disclosed 46 risk factors in its most recent earnings report. Sotera Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sotera Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
HAHAE
79
Outperform
$3.67B22.9918.83%3.95%44.09%
66
Neutral
$3.32B-4.62%7.19%-56.19%
64
Neutral
$4.19B-19.71%-86.13%-67.29%
64
Neutral
$4.56B-111.13%20.54%25.73%
SHSHC
61
Neutral
$3.25B134.415.88%2.78%-54.72%
60
Neutral
$2.89B-10.43%13.54%-30732.00%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SHC
Sotera Health
11.64
-0.11
-0.94%
HAE
Haemonetics
76.24
-8.72
-10.26%
ICUI
ICU Medical
136.18
17.83
15.07%
SGRY
Surgery Partners
22.02
-1.39
-5.94%
IRTC
Irhythm Technologies
142.78
43.27
43.48%
CRSP
Crispr Therapeutics AG
51.67
-1.43
-2.69%

Sotera Health Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Sotera Health Elects Directors and Approves Auditor
Neutral
May 23, 2025

At its 2025 annual meeting on May 21, Sotera Health Company elected three Class II directors for a three-year term, approved executive compensation, and ratified Ernst & Young LLP as its independent auditor for 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market position and stakeholder confidence.

The most recent analyst rating on (SHC) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.

Legal Proceedings
Sotera Health Settles Ethylene Oxide Claims for $30.9M
Negative
Apr 4, 2025

On April 3, 2025, Sterigenics U.S., LLC, a subsidiary of Sotera Health Company, agreed to a settlement of $30,943,000 to resolve 97 ethylene oxide claims related to its former Willowbrook, Illinois facility. The settlement, which requires participation from all claimants and court approval, is not an admission of liability by Sterigenics and is expected to be finalized within 60 to 90 days, potentially impacting the company’s legal standing and stakeholder relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 14, 2025